Alpha-2c-adrenergic receptors contribute to basal nasal patency in the anesthetized cat

Pharmacology. 2010;85(5):259-63. doi: 10.1159/000284581. Epub 2010 Apr 7.

Abstract

Background: Nasal congestion is the most troublesome symptom associated with a variety of upper airway diseases, including allergic rhinitis and the common cold. A better understanding of the mechanisms that regulate nasal cavity caliber may engender the development of novel treatment strategies. It is well accepted that alpha-adrenergic (both alpha(1) and alpha(2)) mechanisms play a fundamental role in the control and maintenance of basal nasal patency. JP-1302 is a selective alpha(2c)-subtype antagonist that has been recently described in the scientific literature. Thus, we sought to examine the potential effects of this new pharmacological tool on basal nasal patency.

Methods: Using acoustic rhinometry, we studied the activity of the selective alpha(2c)-antagonist JP-1302 on nasal cavity volumes in an anesthetized cat. Cumulative concentrations of JP-1302 were applied directly into the right nasal cavity. Changes in the nasal cavity geometry of the drug-treated naris relative to the untreated left nasal cavity were determined. In separate studies, the nonselective alpha(2)-antagonist yohimbine and the nonselective alpha(1)-antagonist prazosin were run as comparators. Systolic blood pressure was measured at the hind leg, using an ultrasonic Doppler flow detector.

Results: JP-1302 (0.03, 0.1, 0.3 and 1.0%) administered by the intranasal route decreased nasal cavity volumes from baseline values by 17, 25, 40 and 40%, respectively. Yohimbine (0.03, 0.1, 0.3 and 1.0%) decreased volumes by 19, 36, 46 and 53%, and topical administration of the nonselective alpha(1)-antagonist prazosin (0.001, 0.003, 0.01, 0.03 and 0.1%) decreased volumes by 6, 47, 56, 64 and 71%, respectively. JP-1302, yohimbine and prazosin, at the dose level tested, did not alter the blood pressure.

Conclusions: The present set of experiments indicates that both alpha(1)- and alpha(2)-adrenergic receptors are involved in the maintenance of basal nasal patency in the cat. Moreover, alpha(2c)-receptors may play a significant role in the sympathetic control of upper airway function.

Publication types

  • Comparative Study

MeSH terms

  • Acridines / administration & dosage
  • Acridines / adverse effects
  • Acridines / pharmacology
  • Administration, Intranasal
  • Adrenergic alpha-1 Receptor Antagonists
  • Adrenergic alpha-2 Receptor Antagonists
  • Adrenergic alpha-Antagonists / administration & dosage
  • Adrenergic alpha-Antagonists / adverse effects
  • Adrenergic alpha-Antagonists / pharmacology
  • Anesthesia
  • Animals
  • Blood Pressure / drug effects
  • Cats
  • Dose-Response Relationship, Drug
  • Male
  • Nasal Cavity / anatomy & histology
  • Nasal Cavity / drug effects
  • Nasal Cavity / physiology*
  • Neurons / drug effects
  • Neurons / physiology*
  • Piperazines / administration & dosage
  • Piperazines / adverse effects
  • Piperazines / pharmacology
  • Protein Isoforms / antagonists & inhibitors
  • Protein Isoforms / physiology
  • Receptors, Adrenergic, alpha-2 / physiology*
  • Rhinitis / drug therapy
  • Rhinometry, Acoustic
  • Sympathetic Nervous System / drug effects
  • Sympathetic Nervous System / physiology*

Substances

  • Acridines
  • Adrenergic alpha-1 Receptor Antagonists
  • Adrenergic alpha-2 Receptor Antagonists
  • Adrenergic alpha-Antagonists
  • JP-1302
  • Piperazines
  • Protein Isoforms
  • Receptors, Adrenergic, alpha-2